Woman sues over spicy restaurant dish, plus viral debate among flight passengers over masks
'LIKE FIRE': A doctor is suing a Thai restaurant after claiming she suffered burns from a spicy meatball dish with bird's eye chilies.
BETTER BODY: Experts say nutrition can strengthen bones with foods that are rich in calcium, vitamin D and other nutrients.
PLANE ANNOYING: As summer travel begins, debates about mask usage on board flights are intensifying on social media.
BUGS BE GONE – Use citronella candles, torches and refillable repellers to prevent bugs from coming around. Continue reading…
CALLING ALL CROSSWORD PUZZLE LOVERS! – Play our Fox News daily crossword puzzle for free here! And not just one — check out the multiple offerings. See the puzzles...
Fox News FirstFox News Opinion
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme（the tradename of Merck & Co., Inc., Rahway, NJ, USA）is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy； OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy； OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech（ a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
2 hours ago
- Associated Press
Dancing Through Menopause Book Announced By Christian Author Betty Johansen
Christian author Betty Johansen has announced 'Dancing Through Menopause,' a faith-based book offering practical strategies for nutrition, exercise, and emotional well-being to help women navigate menopausal changes with confidence and spiritual growth. Big Spring, United States, June 7, 2025 -- Wordsmith World announces the release of 'Dancing Through Menopause,' a new book by Christian author Betty Johansen that addresses physical, hormonal, and emotional aspects of menopause from a faith-based perspective. The book helps Christian women navigate this life transition with confidence and joy while maintaining their spiritual well-being. For more information, visit 'Dancing Through Menopause' provides readers with an understanding of menopausal changes and offers practical strategies for managing symptoms. The book includes a self-assessment section that helps women analyze their unique menopausal experience, along with specific approaches to nutrition, intermittent fasting, and exercise that can alleviate common symptoms and improve overall health. Betty Johansen draws from her background as a former educator, having taught Chemistry, Integrated Physics, and 7th Grade Science before retiring. A lifelong resident of West Texas, Johansen has transitioned from teaching to writing, creating Christian-inspired content that combines practical advice with spiritual guidance. Her scientific background gives her a unique perspective on explaining the biological processes of menopause while her faith informs the spiritual aspects of her approach. 'This book examines the science behind the physical, hormonal, and emotional aspects of menopause while offering ways to overcome its challenges,' said Johansen. 'My goal is to help women develop a healthier and more vibrant lifestyle during this significant transition. The Christian perspective provides an additional dimension of support that many women find valuable during this time.' The book addresses common menopausal symptoms such as weight gain, hot flashes, and mood swings, presenting them as opportunities for personal growth and spiritual development. Johansen encourages readers to view menopause as a new phase in life that can be navigated with grace and faith. The book provides ways to approach these changes with a positive mindset while acknowledging the real challenges they present. Unlike many health books that focus solely on physical symptoms, 'Dancing Through Menopause' takes a holistic approach that considers the whole person—body, mind, and spirit. This integrated method helps women not only manage their symptoms but also find meaning and purpose in this new stage of life. Johansen's writing style makes complex medical information accessible to the average reader while providing depth for those seeking a more thorough understanding. 'Dancing Through Menopause' is now available through the author's website or through Amazon. For additional information about Betty Johansen and her other Christian-inspired works, visit Contact Info: Name: Betty Johansen Email: Send Email Organization: Wordsmith World Address: Texas, Big Spring, Texas 79720, United States Website: Release ID: 89161860 If there are any problems, discrepancies, or queries related to the content presented in this press release, we kindly ask that you notify us immediately at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or support you with press release takedowns. Ensuring accurate and trustworthy information is our unwavering commitment.
Yahoo
3 hours ago
- Yahoo
Log Inn celebrates 200 years of business
OWENSBORO, Ky. (WEHT) — It's a milestone not many businesses anywhere can Log Inn in Haubstadt, Indiana is turning 200 years old. As the oldest restaurant in the state, it holds a lot of history while continuing to serve generations. In the heart of Gibson County, history is served daily on a plate. Built in 1825, The Log Inn has welcomed travelers locals and even President Abraham Lincoln himself in 1844. Now solely a restaurant, it was originally a stagecoach stop. A stagecoach was essential for long distance travelers so they could take breaks and refresh their horses. 'My dad did all the research. [Lincoln] was campaigning for the Clay party, and this was the way he had to go to Vincennes and Terre Haute,' says Trish Epley, the owner of the Log Inn. In the Lincoln room, a special celebration was held to commemorate 200 years of business. '1965 is when it was actually a restaurant. As in log in. But this entire room in the Lincoln room has been in existence for 200 years,' says Cathy Holzmeyer, co-owner of the Log Inn and daughter of Epley. A special plaque and certificate of appreciation was handed over to the Epleys. City leaders and veteran customers joined in the celebration… some who have returned to the tables for over 65 years. 'I couldn't be any happier for the owners because we know the owners. After coming here for 60 some years, you get to know them. They're so sweet, and you want to come back. There chicken is so big and so juicy and flavorful. You know, it's always the same. It's always very consistent,' says Howard Woods, longtime customer of the Log Inn. For the owner Trish Epley it was a full circle moment. At 7-years-old, this used to be the room she shared with her parents and sister. She took ownership from her dad 47 years ago and remembers the night her family accidentally discovered the place was an original log cabin heavy with history. 'We had a storm, and it was on that side of the room that, some weatherboard blew off, and my dad discovered the logs, and that's when we started and tore up all the plaster,' says Epley. She and her daughters work double shifts to serve over 3 thousand stomachs a week — and remain the back drop to generations of family memories. 'I just think it's special. I mean, it's a historical site. It's very unique to everything. I think it's something that we should not ever get rid of,' says Holzmeyer. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
